Details for New Drug Application (NDA): 208912
✉ Email this page to a colleague
NDA 208912 describes DEXYCU KIT, which is a drug marketed by Eyepoint Pharms and is included in one NDA. There are six patents protecting this drug. Additional details are available on the DEXYCU KIT profile page.
The generic ingredient in DEXYCU KIT is dexamethasone. There are thirty-nine drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.
The generic ingredient in DEXYCU KIT is dexamethasone. There are thirty-nine drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.
Summary for 208912
| Tradename: | DEXYCU KIT |
| Applicant: | Eyepoint Pharms |
| Ingredient: | dexamethasone |
| Patents: | 6 |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 208912
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION;INTRAOCULAR | Strength | 9% | ||||
| Approval Date: | Feb 9, 2018 | TE: | RLD: | Yes | |||||
| Patent: | See Plans and Pricing | Patent Expiration: | Jun 22, 2034 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF POSTOPERATIVE INFLAMMATION | ||||||||
| Patent: | See Plans and Pricing | Patent Expiration: | May 23, 2034 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF POSTOPERATIVE INFLAMMATION | ||||||||
| Patent: | See Plans and Pricing | Patent Expiration: | May 23, 2034 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
